Journal
NATURE
Volume 493, Issue 7432, Pages 338-345Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nature11861
Keywords
-
Categories
Funding
- NIH [R01AG039390, R01AG031108, T32AG000057]
- Div Of Molecular and Cellular Bioscience
- Direct For Biological Sciences [1150213] Funding Source: National Science Foundation
Ask authors/readers for more resources
Many experts in the biology of ageing believe that pharmacological interventions to slow ageing are a matter of 'when' rather than 'if'. A leading target for such interventions is the nutrient response pathway defined by the mechanistic target of rapamycin (mTOR). Inhibition of this pathway extends lifespan in model organisms and confers protection against a growing list of age-related pathologies. Characterized inhibitors of this pathway are already clinically approved, and others are under development. Although adverse side effects currently preclude use in otherwise healthy individuals, drugs that target the mTOR pathway could one day become widely used to slow ageing and reduce age-related pathologies in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available